Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daylight photodynamic therapy for actinic keratoses: BF-200 ALA versus MAL
2015-000265-32Phase 4Completed
- Sponsor
- Janne Räsänen
- Start
- Mar 2015
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of 5-aminolevulinic acid and methyl aminolevulinate in actinic keratosis (AK) (2 arms), sponsored by Janne Räsänen. Primary endpoint: Clinical curing of actinic keratosis lesions. Started Mar 2015; status: completed.
02
Drugs
5-aminolevulinic acidmethyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2015-000265-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000265-32.